Phase II study of oxaliplatin, capecitabine, and cetuximab in advanced hepatocellular carcinoma

Authors :: Bert H. O'Neil
Stephen A. Bernard
Carlos E. Marroquin
L. Woods
Dominic T. Moore
Hanna K. Sanoff
Richard M. Goldberg
Reynaldo Garcia
Michael A. Morse
Source :: Journal of Clinical Oncology. 26:4604-4604
Publication Year :: 2008
Publisher :: American Society of Clinical Oncology (ASCO), 2008.
Abstract: 4604 Background: Hepatocellular carcinomas (HCC) are known to express EGFR, and a ph II study of erlotinib suggested clinical activity of EGFR inhibition. Combinations with EGFR and chemotherapies ...

Subjects :: Cancer Research
Cetuximab
business.industry
Egfr inhibition
Phases of clinical research
medicine.disease
digestive system diseases
Oxaliplatin
Capecitabine
Oncology
Hepatocellular carcinoma
medicine
Cancer research
Erlotinib
business
neoplasms
medicine.drug

Full Text Access

Tools